Insmed

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 912

Market Cap: $13.2B

Website

Introduction: Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Clinical Trials

Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa

Phase 3

Withdrawn

Conditions: Cystic Fibrosis

Interventions: Drug: Liposomal amikacin for inhalation
Drug: Placebo for liposomal amikacin for inhalation

First Posted Date: 2011-03-15

Last Posted Date: 2018-07-31

Lead Sponsor: Insmed Incorporated

Registration Number: NCT01315691

Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

Phase 3

Completed

Conditions: Pseudomonas Aeruginosa Infection

Interventions: Drug: Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
Drug: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.

First Posted Date: 2011-03-15

Last Posted Date: 2020-06-16

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 302

Registration Number: NCT01315678

Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria

Phase 2

Completed

Conditions: Mycobacterium Infections, Nontuberculous

Interventions: Drug: placebo
Drug: Liposomal amikacin for inhalation (LAI)

First Posted Date: 2011-03-15

Last Posted Date: 2019-08-21

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 90

Registration Number: NCT01315236

Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: ARIKACE™
Drug: Placebo

First Posted Date: 2008-10-22

Last Posted Date: 2020-07-30

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 66

Registration Number: NCT00777296

Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

Phase 2

Completed

Conditions: Bronchiectasis

Interventions: Drug: Matching Placebo for Cohort 2
Drug: 560 mg Arikayce™
Drug: 280 mg Arikayce™
Drug: Matching Placebo for Cohort 1

First Posted Date: 2008-10-17

Last Posted Date: 2019-07-10

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 64

Registration Number: NCT00775138

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

Phase 2

Completed

Conditions: Myotonic Dystrophy Type 1

Interventions: Drug: placebo
Drug: rhIGF-I/rhIGFBP-3

First Posted Date: 2007-12-20

Last Posted Date: 2022-01-06

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 69

Registration Number: NCT00577577

Locations: 🇺🇸
University of Texas Health Science Center, San Antonio, Texas, United States
🇺🇸
University of Utah, Salt Lake City, Utah, United States
🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

and more 9 locations

Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Arikayce™ 70 mg
Drug: Placebo for 70 mg / 140 mg
Drug: Arikayce™ 560 mg
Drug: Placebo for 560 mg
Drug: Arikayce™ 140 mg

First Posted Date: 2007-11-15

Last Posted Date: 2019-06-04

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 41

Registration Number: NCT00558844

IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome

Phase 2

Completed

Conditions: Growth Hormone Insensitivity Syndrome (GHIS)
Laron Syndrome

First Posted Date: 2006-08-24

Last Posted Date: 2012-09-13

Lead Sponsor: Insmed Incorporated

Registration Number: NCT00368173

Locations: 🇮🇹
Maria Carolina Salerno, Naples, Italy
🇧🇷
Dr. Durval Damiani, Sao Paulo, Brazil
🇦🇺
Dr. Bruce King, Newcastle, Australia

and more 12 locations

Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome

Phase 2

Terminated

Conditions: Noonan Syndrome

First Posted Date: 2006-07-12

Last Posted Date: 2007-03-30

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 24

Registration Number: NCT00351221

Locations: 🇺🇸
Columbus Children's Hospital, Columbus, Ohio, United States
🇺🇸
Schneider Children's Hospital, New Hyde Park, New York, United States

Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung

Phase 1

Completed

Conditions: Osteosarcoma Metastatic

Interventions: Drug: Cisplatin liposomal

First Posted Date: 2005-01-31

Last Posted Date: 2017-08-01

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 19

Registration Number: NCT00102531

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
The Albert Einstein College of Medicine Montefiore Medical Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy